Page last updated: 2024-12-10
sk&f s-106203
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
SK&F S-106203: peptidoleukotriene receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 3035514 |
| MeSH ID | M0179432 |
Synonyms (11)
| Synonym |
|---|
| skf s106203 |
| (3s)-3-(2-carboxyethylsulfanyl)-3-[3-(8-phenyloctyl)phenyl]propanoic acid |
| sk&f 106203 |
| skf 106203 |
| benzenepropanoic acid, beta-((2-carboxyethyl)thio)-3-(8-phenyloctyl)-, (s)- |
| 3-(2-carboxyethylthio)-3-(2-(8-phenyloctyl)phenyl)propanoic acid |
| sk&f-s106203 |
| sk&f s-106203 |
| 129047-98-9 |
| sk&f-s-106203 |
| DTXSID30156044 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "In this report the pharmacologic and pharmacokinetic profile of the leukotriene receptor antagonist 3(S)-[(2-carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl] propanoic acid (SK&F S-106203) in guinea-pigs is described." | ( Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pig. Eckardt, RD; Gleason, JG; Hay, DW; Muccitelli, RM; Novak, LS; Osborn, RR; Sarau, HM; Saverino, CM; Vickery-Clark, LM; Yodis, LA, 1991) | 0.73 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " When given orally, SK&F S-106203 is highly bioavailable and has a very long duration of action which correlates with the pharmacokinetic profile of the compound." | ( Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pig. Eckardt, RD; Gleason, JG; Hay, DW; Muccitelli, RM; Novak, LS; Osborn, RR; Sarau, HM; Saverino, CM; Vickery-Clark, LM; Yodis, LA, 1991) | 0.86 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " SK&F S-106203 produced dose-dependent rightward shifts in the LTC4 and LTE4 dose-response curves." | ( SK&F S-106203 inhibits leukotriene C4, leukotriene D4 and leukotriene E4 vasopressor responses in the conscious rat. Eckardt, RD; Egan, JW; Newton, JF; Slivjak, MJ; Smith, EF, 1990) | 2.63 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.37
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.37) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||